Fluorouracil (5-FU) is an essential component of systemic chemotherapy for colorectal
cancer (CRC) in the palliative and adjuvant settings. Over the past four decades, several …

The impressive clinical activity of small-molecule receptor tyrosine kinase inhibitors for
oncogene-addicted subgroups of non-small-cell lung cancer (for example, those driven by …

We conducted the Reproducibility Project: Cancer Biology to investigate the replicability of
preclinical research in cancer biology. The initial aim of the project was to repeat 193 …

The APOBEC3 family of cytosine deaminases has been implicated in some of the most
prevalent mutational signatures in cancer,–. However, a causal link between endogenous …

Most deaths from cancer are explained by metastasis, and yet large-scale metastasis
research has been impractical owing to the complexity of in vivo models. Here we introduce …

Anticancer uses of non-oncology drugs have occasionally been found, but such discoveries
have been serendipitous. We sought to create a public resource containing the growth …

Drug repositioning is the process of identifying novel therapeutic potentials for existing drugs
and discovering therapies for untreated diseases. Drug repositioning, therefore, plays an …

Dysfunction of the TP53 (p53) gene occurs in most if not all human malignancies. Two
principal mechanisms are responsible for this dysfunction; mutation and downregulation of …

There is a clear and unmet clinical need for biomarkers to predict responsiveness to
chemotherapy for cancer. We developed an in vitro test based on patient-derived tumor …

Cancer is a leading cause of death worldwide. Identifying the best treatment using
computational models to personalize drug response prediction holds great promise to …